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Abstract
Objectives: We conducted this study to evaluate and compare the efficacy of 
azithromycin treatment as an adjunctive therapy to oral hygiene measures in reduc-
ing drug-induced gingival hyperplasia in renal transplant patients under cyclospo-
rine and those under tacrolimus therapy. 
Material & Methods: Patients diagnosed with early to moderate gingival over-
growth with stable allograft function were included in the study. These patients 
had been taking either cyclosporine or tacrolimus for more than 6 months. The 
patients were randomized equally into three groups. Two groups had received 
500-mg azithromycin for 5-days given at baseline only. While the control group 
received placebo in addition to the oral hygiene program .The clinical periodontal 
parameters were assessed and included the plaque index, bleeding on probing 
index, the gingival overgrowth index, and the probing depth. They were evaluated 
at the baseline and at flow up time (1, 3, 6 months).
Results: Seventy five kidney transplant recipients (48 men, 27 women) were in-
cluded in this study. At the baseline time all groups were similar in the clinical 
parameters with no statistically significant difference (P>.05). At follow up time 
intervals all groups showed improvement over baseline measurements however 
both groups who received azithromycin showed more favorable results manifested 
by reduction of gingival bleeding and the depth of gingival sulcus .However, this 
improvement was more in the cyclosporine group than the tacrolimus group and 
the difference was statistically significant (P >.05).
Conclusions: Azithromycin is an effective therapeutic tool in the management of 
drug-induced gingival overgrowth as it is conservative, well tolerated, and rapidly 
effective with minimal side effects; especially in renal transplant patients under 
cyclosporine therapy.
Key words: Gingival hyperplasia, Azithromycin , cyclosporine, tacrolimus.
iMedPub Journals
Our Site: http://www.imedpub.com/
2 © Under License of Creative Commons Attribution 3.0 License
2013
Vol. 3 No. 3:3
doi: 10.3823/735
THE INTERNATIONAL ARABIC JOURNAL 
OF ANTIMICROBIAL AGENTS
Introduction 
The increase in the number and life expectancy of renal trans-
plant patients (RTP) has an impact on oral and dental health 
services. Different oral and dental problems arise in these 
patients, as a direct consequence of drug-induced immuno-
suppression or pharmacokinetics. Attention is now driven on 
the side effects of immunosuppression and on the quality 
of life (1, 2).
Gingival overgrowth (GO) is a well-known complication 
commonly seen with cyclosporine (CsA) and Tacrolimus (Tac) 
which are potent immunosuppressants universally used to 
prevent rejection of organ transplant with selective action on 
T lymphocytes and remarkable improvement in the survival 
rates of transplanted organs especially in renal allograft pa-
tients.(3,4) The prevalence of GO ranges from 20% to 35% 
for CsA treated patients , and approximately 14% for Tac 
group  (5).The concomitant use of calcium channel block-
ers can also increase the severity of this condition. Such a 
variation in individual susceptibility can be as a result of the 
great number of inter-patient variables such as level of plaque 
control (directly correlated); gender (males are three times 
more sensitive); age (inversely correlated); and drug’s daily 
dose (directly correlated (5-7). 
The exact mechanism of cyclosporine-induced gingival hy-
perplasia remains a mystery, multiple mechanisms have been 
postulated like: (a) increased fibroblast stimulation, (b) col-
lagen proliferation, and (c) bacterial-induced gingival inflam-
mation. (8, 9, 10).
GO treatment modalities includes removing bacterial plaque, 
maintaining adequate oral hygiene, and, in some cases, sur-
gical excision (gingivectomy and gingivoplasty). Nevertheless, 
the condition frequently relapses. Therefore to improve qual-
ity of life for those patients new treatment modalities need 
to be used. (10, 11) 
In 1995, the efficacy of the macrolide antibiotic azithromycin 
(AZI) in the resolution of CsA-induced gingival hyperplasia 
was casually observed in two renal transplant recipients treat-
ed for respiratory infection. Subsequent studies confirmed 
these findings. (1-6, 12-15).
Accordingly, we performed this clinical study to investigate 
the effects of AZI as an adjunctive therapy in non-operative 
treatments of drug-induced gingival hyperplasia in (RTP) un-
der CsA and Tac therapy. Up to our knowledge no previous 
research investigated the effect of AZI on Tac induced gingi-
val hyperplasia which prompted this study.
Material and methods
This study was conducted after approval of the ethics com-
mittee at the Urology and Nephrology Centre, Mansoura Uni-
versity, Egypt and the purpose of the study was completely 
explained to each patient before entering the study and in-
formed consents were obtained. The research was carried 
out in accordance with the World Medical Association Dec-
laration of Helsinki on Ethical Principles for Medical Research 
Involving Human Subjects.
Patients 
Seventy five kidney transplant recipients diagnosed to have 
early to moderate GO entered the study. Criteria to enter 
the study were: Stable renal function (no change in serum 
creatine in the last 3 months), cyclosporine- or Tac based im-
munosuppression  nonsmokers both males and females, age 
of > 16 years at the time of the study and no known allergy 
to macrolide antibiotics.
Exclusion criteria of patients were the following: A follow up 
less than 6 month, introduction of calcium-channel blockers 
therapy during the study and impaired renal function due to 
rejection during the therapy.
The quality of oral hygiene was evaluated by a subjective 
score into poor, regular, and good hygiene. This evaluation 
was based on the amount of bacterial plaque present and 
whether there was calculus using plaque disclosing solution.
Initial therapy was performed on all patients and consisted of 
full mouth scaling and root planing, by hand and ultrasonic 
instrumentation, and oral hygiene instruction. The plaque 
score was assessed at each scaling and root planing ses-
sion, and oral hygiene instructions were reinforced. The oral 
hygiene program pursued the following therapeutic model: 
educational and motivational speech on oral hygiene, oral 
hygiene guidelines, and professional dental prophylaxis for 
plaque and calculus removal and home oral hygiene for 30 
days.
This study was a double-blind clinical trial; neither the partici-
pants nor the researchers know which participants belong to 
the control group, as opposed to the test group. Only after 
all data have been recorded and analyzed do the researchers 
know the key that identifies the subjects and which group 
they belonged to.
The patients were randomized equally into three groups. Two 
groups received 500-mg AZI for 5-days given at baseline in 
addition to the oral hygiene program. While the control group 
received placebo in addition to the oral hygiene program.
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Patients were randomized to receive either 500-mg /day of 
AZI or placebo. Trial medication was dispensed in identical 
capsules, prepacked in identical waterproof plastic pouches 
of 5 capsules each, coded using the alphabet. Randomization 
table, allocation details, and trial medication were reserved 
with a no-interest party, and were not revealed to the re-
searchers until the study was over. 
The clinical periodontal parameters were assessed by the 
same periodontist to minimise variability and also who was 
unaware of the treatment modality to eliminate any bias and 
these included: plaque index, bleeding on probing index, Gin-
gival overgrowth index, and Probing depth. These were eval-
uated at the baseline and at follow up time (1, 3, 6 months).
The degree of GO was classified in four categories on the 
basis of hyperplastic index (HI) by Pernu et al, (17): Score 0; 
no GO, score 1; mild GO covering only the gingival one third 
of the tooth crown or less,  score 2; moderated GO extending 
up to the middle of the crown, score 3; severe GO covering 
more than one half of the crown.
Immunosuppressive drug dose and level, time after trans-
plantation, age and gender of the patients were assessed. 
Patients are screened regularly for whole blood and serum 
trough concentrations of CsA or Tac. Creatinine serum read-
ings were measured as a monitor of renal function and were 
available as part of patient’s routine examination on the 
transplant clinics.
Statistical analysis
Data were analyzed using SPSS Statistics software, version 
19.0.0 (SPSS Inc, Chicago, Ill). Variations in the periodontal 
parameters over time were assessed using repeated-measures 
analysis of variance. Intragroup comparisons at follow up time 
(1, 3, 6 months) with baseline assessments were conducted 
using the paired t-test. Intergroup comparisons of the level of 
change in the periodontal parameters compared to baseline 
were conducted at each examination using Student’s t-test.
Results 
Demographic Data
A total 570 patients were screened from the outpatient Renal 
Transplant Clinic of the Urology-Nephrology Centre, Man-
soura University, Egypt. Those patients had received kidney 
transplants between February 1992 to July 2009.
Seventy five patients (48 men, 27 women) who received 
kidney transplants with stable allograft function were re-
cruited. Their mean age was (33.63 ± 13.42 years, range 
17–55 years); and the mean time since transplant was (59.66 
± 45.81 months, range 9–216 months). 
The study groups 
Group I (CsA with GO): twenty five patients, exhibiting 
CsA-induced GO (8 females and 17 males) aged from 20 and 
49 years, mean of 31.6 ± 7.9 years).
Group II (Tac with GO): twenty five patients receiving tac-
rolimus therapy and exhibiting GO(10 females and 15males 
aged from 18 to 50 years, mean of 29.7 ± 9.5 years).
Group III Control group (CsA or Tac with GO): twenty five 
renal transplant patients receiving either CsA or Tac therapy 
with GO (9 females and 16 males aged from 17 to 55, mean 
of 34.6 ± 7.9 years).
At the baseline time the three groups were similar in the 
clinical parameters with no statistically significant difference 
(P>.05). At follow up time intervals both groups who received 
AZI showed improvement over baseline measurements in 
clinical periodontal parameters over the study period (P<.05) 
manifested by reduction of gingival bleeding and the depth 
of gingival sulci. However, this improvement was more in 
the (CsA) group than the (Tac) group and the difference was 
statistically significant (P<.05). (Table 1)
The reported side effects were comparable in the two groups 
with accepted range which include diarrhea, nausea, slight 
abdominal pain and did not necessitate the stopping of the 
treatment in any case. Besides that the pharmacological 
therapy reduced the amount of gum bleeding ,60% of the 
patients reported that the treatment improved their appetite 
greatly as they could chew their food more easily and they 
also reported much easier tooth brushing .
 
AZI has shown effectiveness in reducing the amount of gin-
gival overgrowth in both groups; however, it had a more 
consistent impact in the CsA Group. When the baseline gingi-
val measurements were compared with interval post-therapy 
measurements, there was sustained improvement in gingival 
overgrowth throughout the entire 6 months time period. 
As in CsA group 72% showed complete healing 16% no 
improvement and 12% relapse. In Tac group 48% showed 
complete healing 36% no improvement and 16% relapse. 
While in control group 28% showed complete healing 52% 
no improvement and 20% relapse. And the difference was 
statistically significant between the three groups (P<.05). 
(Figures 1-4) 
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Table 1. Intragroup comparisons of periodontal parameters at different time intervals 
Variable Baseline Mean (SD)
1 month
Mean (SD)
3 month
Mean (SD)
6 month
Mean (SD)
CsA group
PI (% of sites)  93.4 (5.7)  54.6 (9.7)*  50.6 (6.6)**  51.3 (4.6)**
BOP (% of sites)  50.5 (15.7)  15..3 (9.7)**  21.7 (10.5)*  20.7 (8.5)*
PPD (mm)  0.90 (1.0) 0.22 (0.7)**  0.20 (0.9)**  0.25 (0.4)**
GOI (% of sites) 35.7 (12.9) 5.9 (5.5)***  7.8 (3.8)***  8.3 (4.5)***
Tac group
PI (% of sites)  90.3 (4.3)  66.4 (6.5)  64.8 (8.1)*  63.5 (7.5)*
BOP (% of sites)  56.2 (8.3)  25.4 (15.7)*  26.7 (11.4)**  28.7 (10.4)**
PPD (mm)  0.75 (0.9)  0.43 (0.7)  0.37 (0.5)**  0.35 (0.7)**
GOI (% of sites) 37.6 (13.7)  13.3 (10.5)  15.8 (7.5)*  18.8 (5.5)*
Control group
PI (% of sites)  95.3 (4.3)  85.4 (6.5)  83.8 (8.1)*  80.6 (6.6)*
BOP (% of sites)  56.2 (8.3)  50.4 (15.7)*  48.7 (14.4)**  41.7 (12.5)**
PPD (mm)  0.85 (0.6)  0.53 (0.7)  0.31 (0.7)**  0.30 (0.9)**
GOI (% of sites) 37.6 (13.7)  33.3 (7.5)  30.8 (5.5)*  33.0 (5.8)*
* P , .05; ** P , .01; *** P , .001 (paired t-test statistics).
Figure 1.  CsA patient with moderate gingival overgrowth at 
baseline.
Figure 2.  Same patient after 6 months with complete gingival 
healing.
Figure 3.  Tac patient with upper mild and lower moderate 
gingival overgrowth at baseline.
Figure 4.  Same patient after 6 months with gingival 
improvement only in the upper jaw while no 
improvement in the lower jaw.
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Discussion 
Patient compliance with antibiotic regimens is generally a 
problem. However, due to the small number of tablets in 
the course and lack of significant side effects, it is likely that 
compliance is not an issue for people prescribed AZI in the 
present study.
While dentists usually view antibiotics in the context of their 
role in controlling infections, AZI has much broader proper-
ties which potentially account for the improvement in peri-
odontal health. Hirsch et al. (2012) reported that a chronic 
periodonotitis patient receiving AZI treatment without con-
comitant periodontal therapy had alveolar bone regeneration 
raising the intriguing possibility that azithromycin encourages 
bone formation once tissue inflammation has subsided. He 
stated that ‘’it is more than an antibiotic’’ (14).
Pharmacological properties of AZI that makes it a desirable 
agent in the management of dental infections include:  stable 
in acid pH, well absorbed, absorption not affected by food 
, sustained high tissue concentrations ,  extensive penetra-
tion of cells , rapid uptake by phagocytes ,  delivery in high 
concentrations to site of infection , once daily delivery ,and 
short duration of treatment (12).
Following oral administration of AZI, high tissue concentra-
tions are found, which are sustained long after serum con-
centrations have declined to very low levels. AZI extensively 
penetrates cells, including tissue fibroblasts. It is also rapidly 
and extensively taken up by phagocytic cells (polymorpho-
nuclear leukocytes and macrophages). This produces intracel-
lular concentrations far greater than those in the extracellular 
medium. (12-15). 
It is hypothesized that AZI is delivered to a site of infection by 
two mechanisms: Firstly, by direct uptake into tissues, which 
in part is by fibroblasts. Secondly, phagocytes deliver the 
drug to sites of infection where it is released in response to 
phagocytosis producing effective, locally high concentrations 
of the drug by a biological targeted delivery mechanism. The 
preferential uptake by phagocytes leads to concentrations in 
infected tissues, which are much higher than in similar non 
infected sites  (12-15).
GH improvement with the use of AZI might be related to 
the antibiotic effect of this drug, eliminating oral bacteria, 
reducing local inflammation, and decreasing the extracellular 
matrix by fibroblasts. In fact, some researchers observed a 
decrease in the growth of aerobes and spirochetes with the 
use of AZI (9-11). Kim et al. (8) have shown  in their in vitro 
study that AZI blocked fibroblast proliferation and collagen 
synthesis (initiated by cyclosporine) and activated fibroblast 
MMP-2 .
On the other hand, attempts to isolate pathogenic agents in 
gingival fragments with CsA-induced GH were not consis-
tent. (18, 19) Moreover, the beneficial effect of azithromycin 
on GH was not clearly demonstrated with other antibiotics. 
Whereas Mesa et al.   (22) and Aufricht et al. (23) were not 
successful in controlling CsA-induced GH using metronida-
zole for seven days. Moreover, a study testing the efficacy of 
metronidazole and azithromycin in controlling CsA-induced 
GH has shown that the latter was significantly more effec-
tive (20). Further studies are needed to confirm the results 
achieved in this study and to clarify the reasons for the dif-
ferences of response to Azithromycin among renal transplant 
patients.
Conclusion
Azithromycin is an effective therapeutic tool in the manage-
ment of drug-induced gingival overgrowth as it is conserva-
tive, well tolerated, and rapidly effective with minimal side 
effects; especially in renal transplant patients under cyclo-
sporine therapy. Prescription of antibiotics is not substitute 
for adequate debridement, good oral hygiene and regular 
maintenance care.
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